• To understand the role of patient self-efficacy during systemic anticancer therapy
• To learn how pre-assessment for patients undergoing systemic anticancer therapy can improve patient self-efficacy
• To develop ideas for your pre-assessments of patients undergoing systemic anticancer therapy
Maintaining the safety of patients who undergo systemic anticancer therapy (SACT) is a priority and 24-hour acute oncology services have been developed to assist patients in managing treatment-related side effects. Because SACT is mostly delivered in the outpatient setting, healthcare professionals need to be able to rely on patients to recognise and report treatment-related toxicities, which means patients need a high degree of self-efficacy. At University Hospital Southampton NHS Foundation Trust, patients preparing to undergo immunotherapy or chemotherapy take part in a group pre-assessment workshop aimed at improving their self-efficacy.
This article reports the findings of an evaluation of this group pre-assessment workshop. These findings confirm that pre-assessment is a complex intervention that requires adaptability and identifies the need to reiterate information to patients about treatment at every contact with the healthcare team. The group pre-assessment workshop appeared to be acceptable and beneficial to patients but further research is required to determine whether it improves their self-efficacy.
Cancer Nursing Practice. doi: 10.7748/cnp.2021.e1772Peer review
This article has been subject to external double-blind peer review and checked for plagiarism using automated software
Tomlins E, Fisher S, Gifford L et al (2021) Evaluating group pre-assessment for improving self-efficacy in patients undergoing systemic anticancer therapy. Cancer Nursing Practice. doi: 10.7748/cnp.2021.e1772
Acknowledgements The authors would like to thank the advanced nurse practitioners who facilitated the group pre-assessment workshops and the patients who completed the survey
Published online: 28 July 2021
Alternatively, you can purchase access to this article for the next seven days. Buy now